Medline CEO James Boyle Receives Award of 764,252 Incentive Units

What Happened

• James M. Boyle, CEO of Medline Inc. (MDLN), was granted 764,252 performance-based incentive units on August 19, 2026. The filing reports these as derivative awards (no per-share price or immediate cash value is reported). The units were certified as earned by the compensation committee and are fully vested.

Key Details

• Transaction date: August 19, 2026; Form 4 filed August 21, 2026 (filed within the typical 2-business-day Section 16 reporting window).
• Reported acquisition: 764,252 Incentive Units; consideration/price: N/A (derivative award).
• Shares/units owned after transaction: not detailed in the Form 4 filing.
• Footnotes: (1) Units are performance-based and fully vested. (2) They are “profit interests” similar to stock appreciation rights—convertible, at the holder’s election, into a number of Common Units based on the value spread above a participation threshold. (3) Common Units are exchangeable one-for-one for Class A common stock; the Incentive Units have no expiration and are held indirectly through Medline Management Aggregator LLC.

Context

• These Incentive Units are not immediate shares of Medline stock but derivative interests that can be converted into Common Units (and then into Class A shares) only if the value conditions are met and the holder elects conversion. That means no immediate increase in publicly traded shares outstanding from this grant. The award reflects compensation tied to company performance; it does not by itself indicate a buy/sell signal.